Director Barchas Isaac sold 383,200 shares at $21.72–$22.34 for $8.3M; holds 2.03M shares post-sale. IMNM burning cash with -$57.5M net income, -35.5% revenue decline.
Barchas Isaac, a director at Immunome, executed 2 separate sales totaling 383,200 shares for $8,330,079.62, reducing his stake by 15.9% to 2,031,181 shares. The timing coincides with the stock trading at -7.4% from its 52-week high after a +17.3% rebound over 30 days and +94.0% surge over 90 days, suggesting he liquidated during a sharp price recovery. Immunome is an unprofitable biotech burning cash, with latest quarterly revenue at $0.00, net income of -$57,457,000.00 (full-year), and annual revenue declining 35.5%. The large diversification sale by a director during a near-peak rally amid deteriorating fundamentals warrants investor scrutiny of the company's cash runway and clinical progress to validate whether the recent stock appreciation is sustainable.